John Homan, MD
Geriatric Medicine · Tucson, AZNPI 1437116142
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Novo Nordisk at 44.8% of the total. Reporting peaked in 2019 at $12,311 and has fallen 99.9% since, to $18 in 2025. Among geriatric medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $74.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$8K
- AstraZeneca$5K
- AbbVie$3K
- Novartis$289
- Amgen$281
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$254
- plus $2K from 27 others
Across 2 payments — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3K
What the payments were for
- Consulting fees$7,05538%
- Speaking & faculty fees$5,05027%
- Travel & lodging$1,6639%
- Food & beverage$4,61625%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $8,245 |
| AstraZeneca | 34 | $4,544 |
| AbbVie(2 entities) | 45 | $2,991 |
| Novartis | 16 | $289 |
| Amgen | 14 | $281 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $254 |
| Johnson & Johnson | 21 | $193 |
| Smith+Nephew | 3 | $193 |
| GSK | 12 | $189 |
| Pfizer | 7 | $143 |
| Otsuka America Pharmaceutical, Inc. | 6 | $142 |
| Alkermes, Inc. | 1 | $111 |
| Eisai Inc. | 5 | $91 |
| Arbor Pharmaceuticals, Inc. | 5 | $80 |
| Boehringer Ingelheim | 4 | $80 |
| Astellas Pharma US Inc | 4 | $76 |
| Amarin Pharma, Inc. | 4 | $74 |
| Lilly USA, LLC | 4 | $63 |
| Shire North American Group Inc | 2 | $48 |
| Hikma Pharmaceuticals USA | 3 | $46 |
| Vivus LLC | 2 | $36 |
| Eyevance Pharmaceuticals LLC | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Endogastric Solutions, Inc | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Fortovia Therapeutics, Inc. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Bioventus LLC | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 3 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,387 in reported general payments places this provider in the 95th percentile of 75 geriatric medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 137 | $50,851 |
| Bydureon BciseExenatide Microspheres | 26 | $29,656 |
| FarxigaDapagliflozin Propanediol | 18 | $27,139 |
| JanuviaSitagliptin Phosphate | 87 | $26,855 |
| EntrestoSacubitril/Valsartan | 67 | $21,573 |
| MounjaroTirzepatide | 15 | $19,304 |
| Repatha SureclickEvolocumab | 11 | $6,013 |
| Bromocriptine Mesylate | 23 | $5,456 |
| Aripiprazole | 18 | $4,160 |
| Glucagon Emergency KitGlucagon Hcl | 11 | $3,336 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $3,326 |
| Carvedilol ErCarvedilol Phosphate | 14 | $2,509 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $2,394 |
| Pantoprazole Sodium | 86 | $2,090 |
| Levothyroxine Sodium | 116 | $1,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $143 | $50,851137 claims |
| AstraZenecaFarxiga | $4,544 | $27,13918 claims |
| NovartisEntresto | $289 | $21,57367 claims |
| Lilly USA, LLCMounjaro | $63 | $19,30415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 geriatric medicine providers in Arizona.
Other geriatric medicine in Tucson
- John MiglianoTucson$100K
- Ramakrishnan SubbureddiarTucson$7K
- Milan JanskyTucson$2K
- Rama DasariTucson$1K
- Mindy FainTucson$232
- Scott BolhackTucson$175
- Austin WelshTucson$163
- Jaclyn RobinsonTucson$148
- Rosemary BrowneTucson$146
- Julia CremerTucson$117
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.